Search results
Results from the WOW.Com Content Network
This has paved for the way for developing a new gene test for families where pancreatic cancer occurs in multiple family members. [18] Tests for PALB2 have been developed by Ambry Genetics [19] and Myriad Genetics [20] that are now available. Prophylactic mastectomy should be considered for women that had breast cancer and a PALB2 mutation. [21 ...
Database Institute / Organization Alteration Types Primary Source [t 1] Processed Data [t 2] Organisms Cell lines [t 3] Public Data [t 4] Restricted Data [t 5]; The BioExpress® Oncology Suite from Ocimum Bio Solutions contains gene expression data from primary, metastatic, and benign tumor samples, and normal samples, including matched adjacent controls.
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease.
All individuals who are found to carry the inactivated familial CYLD gene mutation should receive genetic counselling which may include: information on limitations in the ability to predict the severity of CCS between individuals, families, and generations; family planning; prenatal testing; preimplantation genetic diagnosis; and the need for ...
The COSMIC (Catalogue of Somatic Mutations in Cancer) database was designed to collect and display information on somatic mutations in cancer. It was launched in 2004, with data from just four genes, HRAS, KRAS2, NRAS and BRAF. [6] These four genes are known to be somatically mutated in cancer. Since its creation, the database has expanded rapidly.
This gives a wider and more global view of cancer genetics, while these data are usually dispersed. [3] It includes a large iconography of about 35,000 images. Dan van Dyke said "This is one stop shopping that unifies cancer genetics information", and Lidia Larizza said that the Atlas was an "interdisciplinary resource".
Oncogenomics is a sub-field of genomics that characterizes cancer-associated genes.It focuses on genomic, epigenomic and transcript alterations in cancer. Cancer is a genetic disease caused by accumulation of DNA mutations and epigenetic alterations leading to unrestrained cell proliferation and neoplasm formation.
The Network of Cancer Genes (NCG) is a freely accessible web resource of genes that, when altered in their sequence, drive clonal expansion of normal tissues (healthy drivers) or cancer (cancer drivers). The project was launched in 2010 and has reached its 7th release in 2022.